Results 131 to 140 of about 60,520 (262)

Regulation of erythropoiesis

open access: yes
Bakalářská práce se zabývá vývojem erytrocytů a faktory ovlivňujícími erytropoézu. V úvodu práce jsou stručně popsány vývojové řady erytropoézy a embryonální vývoj erytropoézy.
Lorencová, Jana
core   +1 more source

Comparative Genomics and Functional Evidence for Convergent Adaptation to Hypoxia in Mammals

open access: yesIntegrative Zoology, EarlyView.
This study reveals convergent selection in mammals adapted to hypoxia. Functional assays demonstrate that amino acid mutations reduce oxidative stress, attenuate hypoxia‐induced injury, and modulate the hypoxia‐inducible transcription factor (HIF)‐driven hypoxic response.
Hao Dong   +5 more
wiley   +1 more source

The role of iron in normal and impaired testicular function

open access: yesAndrology, EarlyView.
Abstract Iron plays a critical role in testicular physiology, impacting spermatogenesis, testosterone production, and overall testicular function. Iron homeostasis is maintained through systemic and cellular regulatory mechanisms, including hepcidin‐mediated systemic iron control and the iron‐responsive element/iron regulatory protein (IRE/IRP) system ...
Aileen Harrer   +2 more
wiley   +1 more source

Limited Clinical Impact of Androgen Receptor Repeat Length (CAG and GGC) in Klinefelter Syndrome: A Multivariable Analysis

open access: yesAndrology, EarlyView.
ABSTRACT Background Klinefelter syndrome (KS) is characterized by marked phenotypic heterogeneity that might be influenced by genetic modifiers, including androgen receptor (AR) repeat length (CAGn and GGCn). The clinical relevance of these repeat lengths in patients with KS before testosterone replacement therapy (TRT) remains unclear.
Andrea Graziani   +8 more
wiley   +1 more source

Molecular insights into stress erythropoiesis

open access: yes, 2007
Purpose of review: In addition to its essential role in baseline erythropoiesis, the hormone erythropoietin drives the erythropoietic response to hypoxic stress.
Socolovsky, Merav
core   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

open access: yesBritish Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo   +3 more
wiley   +1 more source

Megaloblastic Erythropoiesis with Polychromatic Erythroblasts

open access: yes, 2002
megaloblastic erythropoiesis, two polychromatic ...
Lawrence, Christine
core  

A requirement for Lim domain binding protein 1 in erythropoiesis

open access: yes, 2010
During erythrocyte development, the nuclear cofactor Lim domain binding protein 1 (Ldb1) functions as a core subunit of multiprotein DNA binding complexes that include the transcription factors Scl and Gata-1 and the Lim-only adapter Lmo2.
Sang-Hyun Song   +5 more
core   +1 more source

Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies

open access: yesBritish Journal of Haematology, EarlyView.
Gene therapy is revolutionizing treatment paradigms for haemoglobinopathies, establishing a translational framework for disorders that impact red blood cell development. In their paper, Joshi et al. describe the preclinical and early clinical landscape of gene therapies for non‐haemoglobinopathy erythroid disorders and highlight common thematic ...
Gaurav Joshi   +3 more
wiley   +1 more source

Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era

open access: yesBritish Journal of Haematology, EarlyView.
Summary Data on real‐world survival and treatment patterns in large, unselected myelofibrosis (MF) cohorts remain limited. We analysed 1649 patients with MF diagnosed from 2010 onwards and included in the Spanish Myelofibrosis Registry across 64 centres. Janus kinase (JAK) inhibitors were administered to approximately half of the patients.
Juan‐Carlos Hernández‐Boluda   +35 more
wiley   +1 more source

Home - About - Disclaimer - Privacy